EP2154958A4 - TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES - Google Patents

TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES

Info

Publication number
EP2154958A4
EP2154958A4 EP08747605A EP08747605A EP2154958A4 EP 2154958 A4 EP2154958 A4 EP 2154958A4 EP 08747605 A EP08747605 A EP 08747605A EP 08747605 A EP08747605 A EP 08747605A EP 2154958 A4 EP2154958 A4 EP 2154958A4
Authority
EP
European Patent Office
Prior art keywords
spla
inhibitors
secretary
dyslipidemia
phospholipase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08747605A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2154958A1 (en
Inventor
Joaquim Trias
Colin Hislop
Paul Truex
Heather Fraser
Debra Odink
Scott Chadwick
Kenneth Gould
Marian Mosior
Patrick Eacho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anthera Pharmaceuticals Inc
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Publication of EP2154958A1 publication Critical patent/EP2154958A1/en
Publication of EP2154958A4 publication Critical patent/EP2154958A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08747605A 2007-05-03 2008-05-02 TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES Withdrawn EP2154958A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91591007P 2007-05-03 2007-05-03
US96959107P 2007-08-31 2007-08-31
US87486907A 2007-10-18 2007-10-18
PCT/US2008/062577 WO2008137803A1 (en) 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Publications (2)

Publication Number Publication Date
EP2154958A1 EP2154958A1 (en) 2010-02-24
EP2154958A4 true EP2154958A4 (en) 2011-05-04

Family

ID=39943969

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08747605A Withdrawn EP2154958A4 (en) 2007-05-03 2008-05-02 TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES

Country Status (8)

Country Link
EP (1) EP2154958A4 (https=)
JP (1) JP2010526152A (https=)
CN (1) CN101742907A (https=)
AU (1) AU2008247451A1 (https=)
BR (1) BRPI0811486A2 (https=)
CA (1) CA2686157A1 (https=)
EA (1) EA200971020A1 (https=)
WO (1) WO2008137803A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102271507A (zh) * 2009-01-08 2011-12-07 安塞拉制药有限公司 分泌型磷脂酶a2(spla2)抑制剂和烟酸药物组合物以及治疗心血管疾病和血脂异常的方法
RU2483707C1 (ru) * 2012-05-04 2013-06-10 Лира Талгатовна Гильмутдинова Способ санаторной терапии больных с метаболическим синдромом и артериальной гипертензией с применением сульфидных ванн
CN115040508A (zh) * 2022-07-28 2022-09-13 上海市同仁医院 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
WO2002008189A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
EP1378246A1 (en) * 2001-03-19 2004-01-07 Shionogi & Co., Ltd. Remedies for arteriosclerosis
WO2007056281A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
WO2006034435A2 (en) * 2004-09-21 2006-03-30 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
WO2002008189A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
EP1378246A1 (en) * 2001-03-19 2004-01-07 Shionogi & Co., Ltd. Remedies for arteriosclerosis
WO2007056281A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN W M ET AL: "Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A2", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 522, no. 1-3, 3 July 2002 (2002-07-03), pages 113 - 118, XP004369256, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(02)02907-1 *
MA J ET AL: "Are evidence-based cardiovascular prevention therapies being used? A review of aspirin and statin therapies", PREVENTION AND CONTROL, ELSEVIER, NL, vol. 1, no. 4, 1 December 2005 (2005-12-01), pages 285 - 295, XP025337910, ISSN: 1573-2088, [retrieved on 20051201], DOI: 10.1016/J.PRECON.2006.05.002 *
ROBINSON JENNIFER G ET AL: "Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, EXPERT REVIEWS LTD, GB, vol. 4, no. 4, 1 July 2006 (2006-07-01), pages 461 - 476, XP008134541, ISSN: 1744-8344, DOI: 10.1586/14779072.4.4.461 *
RODONDI NICOLAS ET AL: "Aspirin for the primary prevention of cardiovascular disease a comprehensive review", COMPREHENSIVE THERAPY, vol. 31, no. 3, October 2005 (2005-10-01), pages 186 - 193, XP002629623, ISSN: 0098-8243 *
See also references of WO2008137803A1 *
VERVOORDELDONK M J ET AL: "Aspirin inhibits expression of the interleukin-1beta-inducible group II phospholipase A2.", FEBS LETTERS 11 NOV 1996 LNKD- PUBMED:8941724, vol. 397, no. 1, 11 November 1996 (1996-11-11), pages 108 - 112, XP002629622, ISSN: 0014-5793 *
WIKLUND O ET AL: "Effects of simvastatin and atorvastatin on inflammation markers in plasma", JOURNAL OF INTERNAL MEDICINE, vol. 251, no. 4, April 2002 (2002-04-01), pages 338 - 347, XP002629621, ISSN: 0954-6820 *

Also Published As

Publication number Publication date
WO2008137803A1 (en) 2008-11-13
EP2154958A1 (en) 2010-02-24
JP2010526152A (ja) 2010-07-29
CN101742907A (zh) 2010-06-16
CA2686157A1 (en) 2008-11-13
AU2008247451A1 (en) 2008-11-13
EA200971020A1 (ru) 2010-10-29
BRPI0811486A2 (pt) 2014-09-30

Similar Documents

Publication Publication Date Title
FR24C1008I1 (fr) Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire
EP2242768A4 (en) CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
EP2373691A4 (en) ANTI-FXI ANTIBODIES AND METHOD FOR THEIR USE
EP2086583A4 (en) COMPLETELY HUMAN ANTI-VEGF ANTIBODY AND METHOD FOR THEIR USE
DK3323815T3 (en) Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
EP2427479A4 (en) ANTIBODIES AND METHODS OF USE THEREOF
EP1793855A4 (en) MEANS OF PROPHYLAXIS AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE
IL196129A0 (en) Human protein tyrosine phosphatase inhibitors and methods of use
ZA200900558B (en) Human protein tyrosine phosphatase inhibitors and methods of use
EP1942922A4 (en) USE OF COMPLEMENT PATH INGRAMMERS FOR THE TREATMENT OF EYE DISEASES
EP2355849A4 (en) METHOD FOR IMPROVING THE THERAPEUTIC EFFECTIVENESS AND THE THERAPEUTIC UTILIZATION OF ANTIBODY FRAGMENTS
EP1765379A4 (en) PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
EP2563381A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF ISOLEUCYL-TRNA SYNTHETASES
EP2485751A4 (en) METHOD FOR THE TREATMENT OF DEPRESSIONS AND OTHER DISORDERS THEREOF
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
EP1973546A4 (en) CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
EP1933873A4 (en) METHOD AND COMPOSITION FOR USE IN THE TREATMENT OF PATIENTS WITH AUTOANTICODRIVER POSITIVE SUFFERING
EP2321356A4 (en) MONOCLONAL ANTIBODIES TO THE TISSUE FACTOR INHIBITOR (TFPI)
EP2057465A4 (en) ORGANIC PROTEINS AND METHOD OF USE THEREOF
EP2379561A4 (en) MLK INHIBITORS AND METHOD OF USE
EP2627356A4 (en) HUMAN ONCOSTATIN M ANTIBODIES AND METHOD OF USE THEREOF
EP1885388A4 (en) TREATMENT AND ASSESSMENT OF INFLAMMATORY DISEASES
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
EP2048163A4 (en) ANTI-HUMAN ALPHA-9 INTEGRINANT BODY AND ITS USE
EP2432893A4 (en) COMPOSITIONS, KITS AND METHODS FOR IN VITRO-ANTIGEN REPRESENTATION, FOR VERIFYING THE EFFICACY OF A VACCINE, AND FOR VERIFYING THE IMMUNOSIBILITY OF BIOLOGICAL SUBSTANCES AND MEDICAMENTS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139282

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20110401

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20110325BHEP

Ipc: A61K 45/06 20060101ALI20110325BHEP

Ipc: A61K 31/404 20060101ALI20110325BHEP

Ipc: A61K 31/19 20060101ALI20110325BHEP

Ipc: A01N 37/10 20060101AFI20081127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20120829

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1139282

Country of ref document: HK